Chen Weiner

Mr. Chen Weiner


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2022 in The FASEB Journal
Verified
Journal Article
Open access
GSGuy Shapira
Guy Shapira
RHRamzia Abu Hamad
Ramzia Abu Hamad
CWChen Weiner
Chen Weiner
NRNir Rainy
Nir Rainy
RSReut Sorek-Abramovich
Reut Sorek-Abramovich
NSNoam Shomron
Noam Shomron
The concentration of SARS‐CoV‐2‐specific serum antibodies, elicited by vaccination or infection, is a primary determinant of anti‐viral immunity, which correlates with protection against infection and COVID‐19. Serum samples were obtained from 25 897 participants and assayed for anti‐SARS‐CoV‐2 spike protein RBD IgG antibodies. The cohort was composed of newly vaccinated BNT162b2 recipients, in the first month or 6 months after vaccination, COVID‐19 patients and a general sample of the Israeli population. Antibody levels of BNT162b2 vaccine recipients were negatively correlated with age, with a prominent decrease in recipients over 55 years old, which was most significant in males. This trend was observable within the first month and 6 months after vaccination, while younger participants were more likely to maintain stable levels of serum antibodies. The antibody concentration of participants previously infected with SARS‐CoV‐2 was lower than the vaccinated and had a more complex, non‐linear relation to age, sex and COVID‐19 symptoms. Taken together, our data supports age and sex as primary determining factors for both the magnitude and durability of humoral response to SARS‐CoV‐2 infection and the COVID‐19 vaccine. Our results could inform vaccination policies, prioritizing the most susceptible populations for repeated vaccination.

18 October 2019 in Genes
Verified
Journal Article
Open access
PDF file
NSNadav Shoshany
Nadav Shoshany
CWChen Weiner
Chen Weiner
MSMargarita Safir
Margarita Safir
AEAdi Einan-Lifshitz
Adi Einan-Lifshitz
RPRussell Pokroy
Russell Pokroy
EPEran Pras
Eran Pras
Purpose: To identify rare genetic variants in early age-related macular degeneration (AMD) utilizing whole-exome sequencing (WES). Methods: Eight non-related early-AMD families of different Jewish ethnicities were ascertained. Initial mutation screening (phase-1) included common complement factor-H (CFH) p.Y402H; and age related maculopathy susceptibility 2 (ARMS2) p.A69S; and rare variants complement factor-I (CFI) p.V412M; and hemicentin1 (HMCN1) c.4163delC identified previously in our population. Four families, whose initial screening for the aforementioned variants was negative, underwent WES (phase-2). Bioinformatics filtering was based on functionality (from a panel of 234 genes with proven or presumed association to AMD); predicted severity; and frequency (rare variants with minor allele frequency <1%). When applicable, further screening for specific rare variants was carried out on additional cases of similar ethnicities and phenotypes (phase-3). Results: Phase-1 identified three families carrying CFI p.V412M mutation. WES analysis detected probable disease-related variants in three out of the remaining families. These included: a family with a variant in PLEKHA1 gene p.S177N; a family with previously reported variant p.R1210C in CFH gene; and two families with the C3 p.R735W variant. Conclusions: Rare, high-penetrance variants have a profound contribution to early-AMD pathogenesis. Utilization of WES in genetic research of multifactorial diseases as AMD, allows a thorough comprehensive analysis with the identification of previously unreported rare variants.

8 July 2021 in medRxiv
Verified
Preprint
Open access
PDF file
GSGuy Shapira
Guy Shapira
RHRamzia Abu Hamad
Ramzia Abu Hamad
CWChen Weiner
Chen Weiner
NRNir Rainy
Nir Rainy
RSReut Sorek-Abramovich
Reut Sorek-Abramovich
NSNoam Shomron
Noam Shomron
Neutralizing antibodies targeting the Spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) block viral entry to host cells, preventing disease and further spread of the pathogen. The presence of SARS-CoV-2 antibodies in serum is a reliable indicator of infection, used epidemiologically to estimate the prevalence of infection and clinically as a measurement of an antigen-specific immune response. In this study, we analyzed serum Spike protein-specific IgG antibodies from 26,170 samples, including convalescent individuals who had coronavirus disease 2019 (COVID-19) and recipients of the BNT162b2 vaccine. We find distinct serological patterns in COVID-19 convalescent and vaccinated individuals, correlated with age and gender and the presence symptoms.

16 February 2025 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Closed access
CWChen Weiner
Chen Weiner
IHIdan Hecht
Idan Hecht
JLJiri Lindovsky
Jiri Lindovsky
MPMarcela Palkova
Marcela Palkova
MKMichaela Krupkova
Michaela Krupkova
EPEran Pras
Eran Pras

3 September 2026 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Open access
PDF file
MRMoran Landau Rabbi
Moran Landau Rabbi
HMHamutal Meiri
Hamutal Meiri
RMRon Maymon
Ron Maymon
CWChen Weiner
Chen Weiner
YZYonathan Zehavi
Yonathan Zehavi
HCHoward Cuckle
Howard Cuckle
Purpose: Develop a preliminary theoretical model of placental growth factor (PlGF), cell-free DNA fetal fraction (FF) and prior risks in pre-term preeclampsia (PE) and unaffected pregnancies. Methods: Fitting a bivariate Gaussian marker distribution and maternal prior risk factors to a preliminary series. Marker levels were expressed in multiples of the median (MoMs) using fitted regression equations. Unaffected parameters were obtained from the preliminary series; PE parameters from the literature or making reasonable assumptions. Results: 2149 women were tested at 9–14 weeks; pregnancy outcome was not available. Log-linear MoMing equations, after log (PlGF) or square-root (FF) transformation, fitted the data well. Medians in 42 twins were higher than in singletons: PlGF 1.15 and 1.00 MoM, respectively ( P < 0.01); FF 1.35 and 1.01 MoM ( P < 0.0001). There was strong correlation between log PlGF and √FF: in singletons ( R = 0.257, P < 0.0001) and twins ( R = 0.221, although not significant P = 0.16). Applying the model retrospectively, 1 in 60 pre-term PE risk cut-off for singletons and 1 in 12 for twins classified 10.0% as screen-positive. Conclusion: This preliminary theoretical model highlights the parameters requiring modification in a much larger series, and with pregnancy outcome data, before prospective evaluation of combined PlGF and FF screening for PE.

25 June 2022 in medRxiv
Verified
Preprint
Open access
PDF file
GSGuy Shapira
Guy Shapira
CWChen Weiner
Chen Weiner
RSReut Sorek-Abramovich
Reut Sorek-Abramovich
OGOdit Gutwein
Odit Gutwein
NRNir Rainy
Nir Rainy
NSNoam Shomron
Noam Shomron
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in immunocompromised patients may lead to accelerated viral mutation rate, immune evasion and persistent viral shedding over many months. Here we report the case of a severely immunocompromised cancer patient infected with the Delta variant of SARS-CoV-2 for over 8 months. Genome sequencing of samples taken after repeated monoclonal antibody treatments reveal the emergence and accumulation of mutations enabling escape from neutralization by antibodies. Mutations emerging in accessory and non-structural viral proteins target specific residues of immunomodulatory domains, potentially leading to loss of some functions, while preserving others. The mutated virus managed to completely overcome neutralization by monoclonal antibodies while remaining viable and infective. Our results suggest that the loss of specific immunomodulatory viral functions might confer a selective advantage in immunocompromised hosts. We also compare between mutations emerging in the presence and absence of neutralizing antibodies. Highlights: SARS-CoV-2 undergoes rapid evolution in an immunocompromised, chronically infected cancer patient, overcoming neutralization by two monoclonal antibody cocktail treatments Receptor binding domain (RBD) mutations emerging after monoclonal antibody treatment enable effective escape from neutralization in the absence of adaptive immunity Some emerging mutations are predicted to disrupt immunomodulatory viral proteins, including prevention of ORF8 homodimerization, mis-localization of ORF3a in host cells and alteration of the host-suppressive function of NSP1